AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
CHICAGO -- A novel formulation of intravaginal danazol significantly reduced chronic pelvic pain in a small study of women with endometriosis, Dr. Thomas Janicki said in a poster presentation at a meeting sponsored by the International Pelvic Pain Society.
Most importantly, there was a lack of systemic androgenic side effects, and low to undetectable plasma levels of danazol, indicating that the drug was acting locally, said Dr. Janicki, director of the Pelvic Pain Center at University Hospitals of Cleveland.
Treatment with oral danazol in women has been associated with excessive hair growth, weight gain, acne, and deepening of the voice.
The investigational preparation by FemmePharma Inc. of danazol gel that adheres to the vaginal wall was used in the study of 25 women with a prior surgical diagnosis of endometriosis and moderate to severe pain. Dr. Janicki received financial support for his study from FemmePharma and is a scientific advisor and stockholder in the company.
Of the women studied, 16 received 100 mg/day danazol for four menstrual cycles and 9 received 100 mg/day for three cycles and then switched to 200 mg/day for two additional cycles. The patients self-administered the danazol ...
Source: HighBeam Research, Intravaginal danazol gel acts locally to relieve endometriosis...